Previous 10 |
Prothena Corporation PLC (PRTA) Q4 2018 Earnings Conference Call February 14, 2019, 16:30 ET Company Participants Ellen Rose - Head, Communications Gene Kinney - President, CEO & Director Radhika Tripuraneni - Chief Development Officer Wagner Zago - Chief Scientific Officer...
DUBLIN, Ireland, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today that it will report its fourth quarter and full year 2018 financial results on Thursday, February 14 th , after the close of the U.S. financial m...
NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Hyatt Hotels Corporation (NYSE:H), Carter's, Inc. (NYSE:CRI), Globus M...
Prothena (NASDAQ: PRTA ): Q3 GAAP EPS of -$0.62 beats by $0.36 . Revenue of $0.26M (+18.2% Y/Y) beats by $0.03M . Press Release More news on: Prothena Corp plc, Earnings news and commentary, Healthcare stocks news,
Net cash used in operating and investing activities was $33.7 million in the third quarter and $7.5 million in the first nine months of 2018; quarter-end cash and restricted cash position of $455.6 million provides funding to advance neuroscience pipeline DUBLIN, Ireland, Nov. 06, 2018 ...
DUBLIN, Ireland, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and first nine months of 2018 on November 6, 2018 after the close of the U.S. financial markets. Consistent...
News, Short Squeeze, Breakout and More Instantly...
Prothena Corporation plc Company Name:
PRTA Stock Symbol:
NASDAQ Market:
Prothena Corporation plc Website:
2024-07-03 23:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-02 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will initiate a Phase 1 clinical trial for PRX019 in 2024 Prothena Corporation plc (NASDAQ:PRTA),...